Innate Pharma Unveils Promising Preclinical Data for IPH4502 at AACR 2025

Innate Pharma SA ( (FR:IPH) ) has provided an update.

Innate Pharma S.A. presented new preclinical data for its antibody drug conjugate IPH4502 at the AACR 2025 Annual Meeting, highlighting its superior anti-tumor efficacy in various cancer models. The data suggests IPH4502’s potential to overcome resistance in EV-refractory diseases and its broader applicability across multiple tumor types, supporting its ongoing Phase 1 clinical trial in advanced solid tumors.

More about Innate Pharma SA

Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company utilizes innovative approaches to harness the innate immune system through multi-specific NK Cell Engagers, Antibody Drug Conjugates (ADC), and monoclonal antibodies. Innate Pharma collaborates with biopharmaceutical companies like Sanofi and AstraZeneca and is listed on Euronext Paris and Nasdaq.

YTD Price Performance: -50.0%

Average Trading Volume: 1,075

Technical Sentiment Signal: Strong Buy

Current Market Cap: $174.5M

See more data about IPH stock on TipRanks’ Stock Analysis page.